Advertising disclosure — We may earn a commission if you start care through some of these links, at no extra cost to you. How we're funded. Order reflects our editorial rubric and our commercial relationships; scores are ours alone.
Head-to-head for women
HealthSource vs Lttl
HealthSource and Lttl both offer GLP-1 telehealth to women, but they make different trade-offs on PCOS and hormonal suitability, clinical oversight, price and access. Here they are side-by-side on the Luna Fit Score — our women's-health rubric.
HealthSource
Ranked #67 for women · Grade C
Luna Fit
Best for: Women who want an oral tirzepatide option and a documented nationwide footprint, and who will read the four-week billing cycle rather than assuming it is monthly.
Visit HealthSourceLttl
Higher scoreRanked #21 for women · Grade B−
Luna Fit
Best for: Readers treating insulin resistance who want the month-to-month rate rather than a prepay rung, and who will open the plan selector: the real ladder is public, complete and honest, and it is one click from a headline figure that is not.
Visit LttlThe verdict for women
Lttl edges out HealthSource on the Luna Fit Score, 81 to 74 (B− vs C). Readers treating insulin resistance who want the month-to-month rate rather than a prepay rung, and who will open the plan selector: the real ladder is public, complete and honest, and it is one click from a headline figure that is not. The reasoning behind that number is in our Lttl write-up for women.
HealthSource is still a genuine option — one of the few programs that documents its all-50-state footprint rather than asserting it, with an oral tirzepatide route and a starter-dose plan priced the same as the full dose. Weigh the six women's-health factors below against your own priorities; what we found reviewing HealthSource goes through each of them, and if neither of these two is the one, what women pick instead of HealthSource widens the field.
Side-by-side on the six factors
Both providers scored on the same women's-health rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
| Detail | HealthSource | Lttl |
|---|---|---|
| Luna Fit Score | 74/100 · C | 81/100 · B− |
| Overall rank | #67 | #21 |
| Semaglutide | $199 every 4 weeks (13 charges a year; $174.50 per 4 weeks on the 8-week plan) | $199/mo month-to-month (from $129/mo on a 12-month plan billed $1,548 up front) — the product card advertises the $129 rung |
| Tirzepatide | $299 every 4 weeks (13 charges a year; $274.50 per 4 weeks on the 8-week plan) | $279/mo month-to-month (from $199/mo on a 12-month plan billed $2,388 up front) — the product card advertises $129, which no tirzepatide tier costs |
| Coverage | All 50 states | All 50 states plus Washington D.C., with a stated caveat that some services may not be |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Luna Fit
HealthSource
Ranked #67 · Grade C
What we like
- The only provider in this batch whose all-50-state claim is documented on its own service-areas page rather than asserted in marketing copy
- An oral tirzepatide program alongside the injections
- Starter-dose and full-dose plans cost the same, so titrating up does not raise the bill
The caveats
- Billed every four weeks, not monthly — thirteen charges a year, so the effective annual cost is about 8% above the sticker
- Never actually claims flat pricing across all doses; the variants it sells happen to cost the same
- The form of the oral tirzepatide — sublingual, troche or swallowed tablet — is not disclosed anywhere
Luna Fit
Lttl
Ranked #21 · Grade B−
What we like
- Publishes its entire price ladder — every product, every term, every rung — in the public page source, each one labeled with what it bills (“$199/mo every month” beside “$1,548 annually”), with no intake quiz standing between you and the number
- A genuine month-to-month rung exists and is purchasable for every product, with no contracts and no minimum term, so the prepay ladder is an optional discount rather than the only way in
- Both molecules across three routes — injection, orally disintegrating tablet, and lower-dose microdose lines sold as their own products with their own published ladders rather than quoted at the full-dose price
The caveats
- All fourteen product cards hardcode “from $129/mo”. For semaglutide that is the twelve-month rung billed $1,548 up front; for tirzepatide, the semaglutide ODT and the microdose ODT it is a price purchasable at no tier at all
- The month-to-month rates are roughly 40% above the advertised figure — $199 for semaglutide and $279 for tirzepatide against the $129 on every card
- Names no medical director and no prescribing clinician, offers and requires no labs or bloodwork, and carries no third-party certification such as LegitScript
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. Pricing, states and verification reflect each provider's public disclosures at last review; the Luna Fit Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Neither HealthSource nor Lttl is only worth comparing with the other. HealthSource is also written up against CoreAge Rx, 19 points apart on the Luna Fit Score — see how HealthSource and CoreAge Rx compare on the Luna Fit Score. Lttl is also written up against CoreAge Rx, 12 points apart — see Lttl against CoreAge Rx, factor by factor.
- HealthSource vs CoreAge Rx
- HealthSource vs Enhance MD
- HealthSource vs Eden
- Lttl vs yourEra
- Lttl vs Sesame Care
- Lttl vs HealthRX
Or browse the full comparison hub.